Requests that FDA declare that Guanfacine Extended-Release Powder for Oral Suspension, 1 mg/mL, is suitable for submission as an ANDA
🏛 Food and Drug Administration (FDA)FDA-2025-P-7432
Documents
3
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
📄 Primary document
- Other· Dec 31, 2025No comment period